Literature DB >> 20199502

Recurrent primary biliary cirrhosis after liver transplantation.

M G Silveira1, J A Talwalkar1,2, K D Lindor1, R H Wiesner1,2.   

Abstract

Recurrent primary biliary cirrhosis (PBC) is an important clinical outcome after liver transplantation (LT) in selected patients. Prevalence rates for recurrent PBC (rPBC) reported by individual LT programs range between 9% and 35%. The diagnostic hallmark of rPBC is histologic identification of granulomatous changes. Clinical and biochemical features are frequently absent with rPBC and cannot be used alone for diagnostic purposes. Some of the risk factors of rPBC may include recipient factors such as age, gender, HLA status and immunosuppression, as well as donor factors such as age, gender and ischemic time, although controversy exists. Most patients have early stage disease at the time of diagnosis, and there may be a role for therapy with ursodeoxycholic acid. While short- and medium-term outcomes remain favorable, especially if compared to patients transplanted for other indications, continued follow-up may identify reduced long-term graft and patient survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20199502     DOI: 10.1111/j.1600-6143.2010.03038.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  13 in total

Review 1.  Primary biliary cirrhosis and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara
Journal:  Intractable Rare Dis Res       Date:  2012-05

Review 2.  Recurrence of autoimmune liver diseases after liver transplantation.

Authors:  Nabiha Faisal; Eberhard L Renner
Journal:  World J Hepatol       Date:  2015-12-18

Review 3.  The Cholangiopathies.

Authors:  Konstantinos N Lazaridis; Nicholas F LaRusso
Journal:  Mayo Clin Proc       Date:  2015-05-06       Impact factor: 7.616

4.  Innate immunity drives xenobiotic-induced murine autoimmune cholangitis.

Authors:  C-H Chang; Y-C Chen; Y-H Yu; M-H Tao; P S C Leung; A A Ansari; M E Gershwin; Y-H Chuang
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

5.  Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis.

Authors:  Mio Kobayashi; Yuko Kakuda; Kenichi Harada; Yasunori Sato; Motoko Sasaki; Hiroko Ikeda; Mitsuhiro Terada; Munenori Mukai; Shuichi Kaneko; Yasuni Nakanuma
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

6.  Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study.

Authors:  Tomomi Kogiso; Hiroto Egawa; Satoshi Teramukai; Makiko Taniai; Etsuko Hashimoto; Katsutoshi Tokushige; Shotaro Sakisaka; Satomi Sakabayashi; Masakazu Yamamoto; Koji Umeshita; Shinji Uemoto
Journal:  Hepatol Commun       Date:  2017-05-16

Review 7.  Essential updates 2018/2019: Liver transplantation.

Authors:  Masahiro Ohira; Naoki Tanimine; Tsuyoshi Kobayashi; Hideki Ohdan
Journal:  Ann Gastroenterol Surg       Date:  2020-02-25

8.  The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort.

Authors:  Greta Pells; George F Mells; Marco Carbone; Julia L Newton; Andrew J Bathgate; Andrew K Burroughs; Michael A Heneghan; James M Neuberger; Darren B Day; Samantha J Ducker; Richard N Sandford; Graeme J Alexander; David E J Jones
Journal:  J Hepatol       Date:  2013-03-04       Impact factor: 25.083

9.  Plasma cell neoplasms in US solid organ transplant recipients.

Authors:  Eric A Engels; Christina A Clarke; Ruth M Pfeiffer; Charles F Lynch; Dennis D Weisenburger; Todd M Gibson; Ola Landgren; Lindsay M Morton
Journal:  Am J Transplant       Date:  2013-05-01       Impact factor: 9.369

10.  APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.

Authors:  Hong You; Xiong Ma; Cumali Efe; Guiqiang Wang; Sook-Hyang Jeong; Kazumichi Abe; Weijia Duan; Sha Chen; Yuanyuan Kong; Dong Zhang; Lai Wei; Fu-Sheng Wang; Han-Chieh Lin; Jin Mo Yang; Tawesak Tanwandee; Rino A Gani; Diana A Payawal; Barjesh C Sharma; Jinlin Hou; Osamu Yokosuka; A Kadir Dokmeci; Darrell Crawford; Jia-Horng Kao; Teerha Piratvisuth; Dong Jin Suh; Laurentius A Lesmana; Jose Sollano; George Lau; Shiv K Sarin; Masao Omata; Atsushi Tanaka; Jidong Jia
Journal:  Hepatol Int       Date:  2022-02-04       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.